Tag: sglt2 inhibitors

1. Sotagliflozin was shown to lower the risk of total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure in patients with diabetes and recent worsening heart failure compared to placebo. 2. Sotagliflozin was shown to be similar in the percentage of patients with adverse...

1. In this descriptive case series, 55 cases of patients with diabetes who developed Fournier gangrene while using sodium-glucose cotransporter-2 (SGLT2) inhibitors are described. 2. While neither causality nor incidence are identified in this paper, physicians prescribing SGLT2 inhibitors should be aware of the association with Fournier gangrene. Evidence Rating Level:...

1. Canagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, significantly reduced the risk of the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in patients with type 2 diabetes when compared to placebo. 2. Patients treated with canagliflozin experienced significantly higher rates of amputation, fracture, and...

1. In patients with type 2 diabetes and an estimated glomerular filtration (eGFR) rate of ≥ 30 mL per minute per 1.73 m2 of body-surface area that received empagliflozin, there was reduced incidence of new or worsening nephropathy, less incidence of doubling of creatinine and less initiation of renal-replacement...